GeoVax Labs, Inc. — Q2 2017 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2017; financial statements are unaudited. GeoVax is a clinical-stage vaccine developer. Its preventive HIV vaccine was in human trials; other disclosed programs were in preclinical development. It had no product sales and did not expect product revenue for several years.
Financial results and liquidity
| Metric | Q2 2017 | Q2 2016 | Six months 2017 | Six months 2016 |
|---|---|---|---|---|
| Grant and collaboration revenue | $352,137 | $166,280 | $647,872 | $213,880 |
| Research and development | $518,098 | $397,576 | $1,069,893 | $835,580 |
| General and administrative | $352,191 | $344,818 | $644,858 | $1,251,323 |
| Net loss | $(516,881) | $(575,835) | $(1,065,222) | $(1,872,114) |
| Loss per common share | $(0.01) | $(0.02) | $(0.02) | $(0.05) |
At June 30, cash and cash equivalents were $822,597, total current assets $933,617, current liabilities $651,592, working capital $282,025, and total assets $990,009. Stockholders’ equity was $338,417. The filing reports no long-term debt or committed credit line. No gross margin is presented; grant revenue is recognized as reimbursable costs are incurred, and the filing does not provide a clear product-margin measure.
For the first six months, operating cash use was $761,250, investing cash use was $4,350, and financing cash inflow was $1,134,167. Financing included $980,000 net proceeds from Series D preferred stock and $154,167 net proceeds from warrant exercises. Cash increased by $368,567 from year-end 2016.
Material changes versus prior periods
- Six-month revenue rose to $647,872 from $213,880, largely reflecting higher grant activity and a $95,000 upfront collaboration fee from American Gene Technologies International (AGT).
- Six-month R&D expense increased to $1,069,893 from $835,580. G&A fell to $644,858 from $1,251,323; the 2016 comparison included $469,799 of warrant-modification compensation expense. Excluding stock-based compensation, six-month G&A was $629,018 in 2017 versus $765,939 in 2016.
- The six-month net loss narrowed to $1,065,222 from $1,872,114. Operating cash use also declined from $1,174,416 to $761,250.
- In May 2017, GeoVax issued 1,000 Series D preferred shares for $1.0 million gross proceeds. The issuance triggered a reduction in the Series C conversion price from $0.05 to $0.015 per common share. Series D also has an initial $0.015 conversion price and price-adjustment provisions.
- Common shares outstanding were 62,913,900 at June 30 and 66,913,900 as of August 14, 2017. Stockholders approved an increase in authorized common shares from 300 million to 600 million in August.
Outlook, risks, and other notable items
- Management said cash and government funding commitments were expected to support planned operations through the end of 2017. Additional capital is required beyond that point. The filing states there is substantial doubt about the company’s ability to continue as a going concern beyond 2017; management’s funding plans do not alleviate that doubt. Funding may not be available on favorable terms or at all, and programs could be delayed, scaled back, or eliminated.
- GeoVax reported $910,774 of approved grant and contract funds available at June 30, including funds available through June 2018. Grant revenue depends on eligible expenditures and timing. It also disclosed a contract of up to $7.8 million awarded by NIAID in 2016 for production of a DNA vaccine component.
- Accrued management salaries and director fees of $484,638 were being deferred at June 30. Lease payments and other firm purchase obligations totaled approximately $390,000; about $158,000 of purchase commitments were expected to be reimbursed under government grants.
- AGT intends to conduct a Phase 1 trial combining its technology with GeoVax’s for a potential functional cure for HIV; AGT bears the trial costs. The $95,000 fee was recorded as revenue, and no commercial rights or licenses had been granted.
- Potential dilution is significant: approximately 285.5 million common-share equivalents were excluded from diluted loss per share as anti-dilutive. Series C preferred shares were convertible into approximately 187.3 million common shares at June 30; Series D price-adjustment terms could affect conversion economics.
- Management identified development, regulatory approval, competition, and ability to raise capital as key uncertainties. It reported no material changes to previously disclosed risk factors, no legal proceedings, and effective disclosure controls.
Important facts for investors to verify
- Cash runway assumptions and whether new grants, contracts, equity financing, or warrant exercises provide adequate funding beyond 2017.
- Progress and funding status of HIV trials, the NIAID-supported programs, and the planned AGT collaboration trial.
- Potential common-share dilution from Series B, C, and D preferred stock, warrants, and other outstanding share equivalents, including Series D price adjustments.
- Whether deferred management and director compensation is paid, and whether grant reimbursements cover the disclosed purchase commitments.
- Timing and terms of future capital raises, and the company’s progress toward resolving the disclosed going-concern uncertainty.